Protocols

Loxo raising $227M in post-ASCO score; Bavarian Nordic reports data delay; Sonar and Stratus ordered to cease production

→  Loxo shared some impressive data at ASCO, and the biotech isn’t about to let that pass without raising more cash. The company announced a public offering of 3,150,000 shares of common stock at of $72.00 per share. They’re expecting $226.8 million in proceeds when they close on June 20.

 Bavarian Nordic has announced a delay in reporting data from its PROSPECT study, a Phase III trial to test the efficacy of PROSTVAC on the survival of men with metastatic castration-resistant prostate cancer. The company says the delay is due to a decrease in average monthly events in the study. Results are still expected this year.

→  After US Marshalls seized more than $16 million worth of unapproved and misbranded prescription drugs from a Stratus facility and investigators found microbial levels that were “too numerous to count,” a South Florida judge ordered Status and Sonar to cease production of drugs that are unapproved, mislabeled or contaminated. Miami-based Stratus and New Jersey-based Sonar reportedly have histories of violating CGMPs.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 24,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Immuno Oncology 360

Bio NJ Annual Dinner